The largest database of trusted experimental protocols

Dragen 2 platform

Manufactured by Illumina

The DRAGEN 2 platform is a high-performance computing solution designed for genomic analysis. It provides hardware-accelerated processing of next-generation sequencing data, enabling rapid and efficient bioinformatics workflows.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using dragen 2 platform

1

Trio Exome Sequencing for Mosaic SNVs

Check if the same lab product or an alternative is used in the 5 most similar protocols
We analyzed family trio ES data from approximately 15,000 patients enrolled in clinical diagnostic studies. Average depth-of-coverage was ~100x with >70% of reads aligned to target, >95% target base covered at >20x, >85% target base covered at >40x. Since ES data in BG have been pre-processed using a different analytical pipeline than BHCMG cohort, we modified the mosaic SNV candidate selection accordingly. We have used three different data subsets, as presented in Supplementary Figure 1. The first subset of parental mosaic variants was derived from the analysis of 3165 apparent de novo heterozygous SNVs in the probands selected previously in the process of clinical analysis. Second subset consists of approximately 1000 trios for which joint VCF files were generated on the Illumina DRAGEN 2 platform. We focused on unique rare variants that occurred in only one family. We also removed any variants that overlapped segmental duplications. Similar to the approach used for the BHCMG cohort, we required a depth of at least 20 reads in each parent, an evidence of heterozygous state in the proband with a VAF of 0.3-0.7 and 0
+ Open protocol
+ Expand
2

Trio Exome Sequencing for Mosaic SNVs

Check if the same lab product or an alternative is used in the 5 most similar protocols
We analyzed family trio ES data from approximately 15,000 patients enrolled in clinical diagnostic studies. Average depth-of-coverage was ~100x with >70% of reads aligned to target, >95% target base covered at >20x, >85% target base covered at >40x. Since ES data in BG have been pre-processed using a different analytical pipeline than BHCMG cohort, we modified the mosaic SNV candidate selection accordingly. We have used three different data subsets, as presented in Supplementary Figure 1. The first subset of parental mosaic variants was derived from the analysis of 3165 apparent de novo heterozygous SNVs in the probands selected previously in the process of clinical analysis. Second subset consists of approximately 1000 trios for which joint VCF files were generated on the Illumina DRAGEN 2 platform. We focused on unique rare variants that occurred in only one family. We also removed any variants that overlapped segmental duplications. Similar to the approach used for the BHCMG cohort, we required a depth of at least 20 reads in each parent, an evidence of heterozygous state in the proband with a VAF of 0.3-0.7 and 0
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!